Kamada: Trial shows Glassia effective against lung disease

The results of preclinical trials of its AAT protein may promote the company's activity in the diabetes field and help it enter other fields

Drug developer Kamada Ltd. (TASE: KMDA) today announced positive results in a preclinical trial of its Alpha-1 Antitrypsin (AAT) protein, the active ingredient in its drug, Glassia, which may promote the company's diabetes activity and help it enter other fields.

The results of the preclinical trial showed that the AAT protein targets the activity of B-lymphocytes (a type of white blood cell that produces antibodies) to help deal with implant rejection, raising the chances of success of a range of implants.

The preclinical study, conducted at Ben Gurion University in the Negev, found that the presence in mice blood of the AAT protein, which is the same protein as in Glassia, resulted in the creation of protective substances in the blood in significantly larger quantities compared with the control group.

A separate preclinical trial of Glassia found, for the first time, that the condition of laboratory mice with bacterial lung infections, treated with Glassia, was significantly better than the control group, which was not treated with the drug.

Kamada CEO David Tsur said, "These results on animals are a positive indication of the effectiveness of our drug, and make it more worthwhile to develop the drug for other indications. The preclinical results are further validation of the future development strategy of the company and its ability to enter other indications with great business potential in the future."

Published by Globes [online], Israel business news - www.globes-online.com - on November 5, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018